Vitamin K: the effect on health beyond coagulation – an overview

VitaK and Cardiovascular Research Institute CARIM, Maastricht University, Maastricht, The Netherlands.
Food & Nutrition Research (Impact Factor: 1.79). 04/2012; 56. DOI: 10.3402/fnr.v56i0.5329
Source: PubMed

ABSTRACT Vitamin K is essential for the synthesis of proteins belonging to the Gla-protein family. To the members of this family belong four blood coagulation factors, which all are exclusively formed in the liver. The importance of vitamin K for hemostasis is demonstrated from the fact that vitamin K-deficiency is an acute, life-threatening condition due to excessive bleeding. Other members of the Gla-protein family are osteocalcin, matrix Gla-protein (MGP), and Gas6 that play key functions in maintaining bone strength, arterial calcification inhibition, and cell growth regulation, respectively. In total 17 Gla-proteins have been discovered at this time. Recently, it was observed that the dietary vitamin K requirement for the synthesis of the coagulation factors is much lower than for that of the extra-hepatic Gla-proteins. This forms the basis of the triage theory stating that during poor dietary supply, vitamins are preferentially utilized for functions that are important for immediate survival. This explains why in the healthy population all clotting factors are synthesized in their active form, whereas the synthesis of other Gla-proteins is sub-optimal in non-supplemented subjects. Prolonged sub-clinical vitamin K deficiency is a risk factor for osteoporosis, atherosclerosis, and cancer. Present recommendations for dietary intake are based on the daily dose required to prevent bleeding. Accumulating scientific data suggests that new, higher recommendations for vitamin K intake should be formulated.

  • Food & Nutrition Research 04/2012; 56. DOI:10.3402/fnr.v56i0.17206 · 1.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Metabolic Syndrome (MetS) is a cluster of metabolic abnormalities and is associated with increased risk of diabetes and cardiovascular diseases. Phylloquinone, menaquinones and vitamin K status are associated with several components of MetS, but the association with MetS has hardly been studied to date. To examine whether the intake and/or status of vitamin K is associated with MetS and its components. This study comprised of two cohorts, one of 402 women and one of 400 men (40-80 years). At follow-up 625 participants were still alive and willing to participate. Data were analyzed both cross-sectionally and longitudinally with Poisson and linear regression adjusted for multiple confounders. Baseline phylloquinone/menaquinone intakes were measured with a validated food frequency questionnaire and vitamin K status with serum desphospho-uncarborxylated matrix-Gla protein level. At baseline 270(34.5%) participants had MetS and 171(35.7%) at follow-up. Cross-sectionally, high menaquinones intakes were associated (Ptrend=0.08) with a lower prevalence of MetS with a prevalence ratio (PR) of 0.74 (95%CI: 0.54;1.03) for the highest versus the lowest tertile. At follow-up, the highest tertiles of menaquinones intake (PR=0.62, 95%CI: 0.40;0.95) and vitamin K status (PR=0.57, 95%CI: 0.38;0.87) were associated (Ptrend=0.01) with a lower occurrence of MetS. These associations were mainly driven by relations with lower triacylglycerol concentrations for menaquinones and lower waist circumference for vitamin K status. Phylloquinone intake was not associated with MetS prevalence. This study shows that a high intake of menaquinones and high vitamin K status are associated with a lower occurrence of MetS.
    The Journal of Clinical Endocrinology and Metabolism 04/2015; DOI:10.1210/jc.2014-4449 · 6.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With the discovery that vitamin K-dependent matrix Gla-protein (MGP) is a strong and modifiable factor in the prevention of arterial calcification, vitamin K was put forward as novel treatment option in cardiovascular disease. The vasculoprotective properties of vitamin K are in part based on the ability to improve gamma-glutamylcarboxylation of MGP, which is a prerequisite for MGP as a calcification inhibitor. Data from experimental animal models reveal that high intake of vitamin K can prevent and even reverse vascular calcifications. In addition, clinical data demonstrate that prescription of vitamin K antagonists for long-term oral anticoagulant therapy accelerates vascular calcification. However, controlled data from randomized prospective vitamin K interventional trials are lacking, thereby weakening a general recommendation for supplementation. The present article summarizes our current knowledge on the association between vitamin K and cardiovascular health. Additionally, we focus on an outlook on important ongoing prospective vitamin K intervention studies. These studies address the issues whether vitamin K substitution helps modifying relevant cardiovascular surrogates such as vascular calcification and whether non-vitamin K oral anticoagulants provide an alternative to support cardiovascular health benefits. So research about cardiovascular protection by vitamin K is an evolving field in which we expect a boost of novel and relevant evidence shortly. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    Atherosclerosis 02/2015; 240(1):10-16. DOI:10.1016/j.atherosclerosis.2015.02.040 · 3.97 Impact Factor